Paul Beswick

The paper identifies and optimizes bicyclic peptide inhibitors of Staphylococcus aureus α-hemolysin, achieving sub-micromolar affinity and demonstrating functional inhibition of toxin activity.

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.

This study discovers and optimizes bicyclic peptide inhibitors of E. coli PBP3, showing high-affinity binding and broad-spectrum antimicrobial activity.